Mitochondrial respiration, the key process behind cellular energy production, is critical for cell proliferation, growth and survival. However, the regulation of mitochondrial respiratory function in tumor cells is not well understood. In this study, we propose a model whereby tumor cells possess the capacity to fine-tune the balance between energy demands and mitochondrial reactive oxygen species (ROS) status, to maintain a milieu optimal for survival. This is achieved through the moderation of mitochondrial respiration, depending on the ROS context within the organelle, with the main players being Bcl-2 and cytochrome c oxidase (COX). We report a higher level of COX activity, oxygen consumption and mitochondrial respiration in tumor cells overexpressing Bcl-2. Transient overexpression, gene silencing and pharmacological inhibition of Bcl-2 corroborate these findings. Interestingly, Bcl-2 is also able to regulate mitochondrial respiration and COX activity in the face of mounting ROS levels, triggered by mitochondrial complex inhibitors. In this respect, it is plausible to suggest that Bcl-2 may be able to create an environment, most suited for survival by adjusting mitochondrial respiration accordingly to meet energy requirements, without incurring an overwhelming, detrimental increase in intracellular ROS. Cancer is a multifactorial disease orchestrated by dysregulated cellular pathways that control cell fate decisions. Despite recent strides in our understanding of the biology of the transformed phenotype, several critical effector pathways remain unexplained. Among these, the involvement of mitochondrial respiration and function in the process of carcinogenesis is far from clear. Recent interest has focused on the role of metabolism such as mitochondrial respiration and the glycolytic pathway, whereby p53 was shown to be involved in both by mediating the expression of TP53-induced glycolysis and apoptosis regulator and synthesis of cytochrome c oxidase (COX) 2.
Cancer is a multifactorial disease orchestrated by dysregulated cellular pathways that control cell fate decisions. Despite recent strides in our understanding of the biology of the transformed phenotype, several critical effector pathways remain unexplained. Among these, the involvement of mitochondrial respiration and function in the process of carcinogenesis is far from clear. Recent interest has focused on the role of metabolism such as mitochondrial respiration and the glycolytic pathway, whereby p53 was shown to be involved in both by mediating the expression of TP53-induced glycolysis and apoptosis regulator and synthesis of cytochrome c oxidase (COX) 2. [1] [2] [3] However, little correlation has been shown to address whether the effect of antiapoptotic proteins such as Bcl-2 extends to mitochondrial function, pertaining to the electron transport chain (ETC) and mitochondrial respiration. Bcl-2 is largely localized to the mitochondria, with many of its protective effects centering on mitochondrial membrane integrity and sequestration of proapoptotic proteins. [4] [5] [6] However, mitochondrial respiration, a major source of reactive oxygen species (ROS), remains loosely connected to this 'resident' protein of the mitochondria. 7, 8 Recent work paved the way for a possible link between Bcl-2 and mitochondrial respiration by suggesting that leukemia cells overexpressing Bcl-2 promote a slight pro-oxidant state, permissive for cell survival. 9 The role of Bcl-2 as a pro-oxidant protein in live animal models has also been reflected in other model systems. 10 If this scenario were indeed true, it would be of great interest to identify the cellular source(s) of superoxide
). Because the mitochondria has been widely regarded as the main consumer of molecular oxygen as well as ROS production, it appears logical to investigate the role of mitochondria in this pro-oxidant state. 7, 8 Given the localization of Bcl-2 to the mitochondria it became compelling to investigate if the protein plays a role in generating a slight pro-oxidant state by engaging the mitochondria machinery. 7, 8, 11, 12 One of the key mitochondrial proteins is COX, the fourth complex and the rate-limiting step of the ETC, where it expends the majority of oxygen for reduction by cytochrome c to produce water, and as a result generates adenosine triphosphate (ATP) via oxidative phosphorylation. 2, 13 Given the antiapoptotic nature of Bcl-2 and the functional significance of COX in mitochondrial respiration, here we investigated the role of Bcl-2 in mitochondrial respiration with relation to COX and the subsequent downstream effects. We present evidence that cancer cells overexpressing Bcl-2 have greater basal COX activity and oxygen consumption as compared to mock-transfected cells. More intriguingly, an abundance of Bcl-2 empowers the cell to sense mitochondrial oxidative stress and respond by regulating mitochondrial respiration accordingly at the level of COX, and in so doing maintains mitochondrial ROS status at a manageable level. With these findings, we propose a model whereby Bcl-2 is able to promote mitochondrial respiration under normal conditions for a pro-oxidant state to drive proliferation signals. However, in the wake of stress triggers such as overwhelming ROS production, Bcl-2 regulates mitochondrial respiration and draws the line between the need for energy and keeping ROS levels under homeostatic control, so as to increase the cancer cell's propensity to survive under harsh conditions.
Results
CEM/Bcl-2 cells exhibit higher levels of intracellular and intramitochondrial O 2 À than CEM/Neo cells. Although previous reports suggest an antioxidant function for Bcl-2 by reinforcing cellular antioxidative defenses in response to its self-induced ROS production, our observations provide insight into the role of Bcl-2 in creating a slight pro-oxidant intracellular milieu in tumor cells. [14] [15] [16] Corroborating our earlier report, CEM/Bcl-2 cells had moderately higher levels of O 2 À than CEM/Neo cells ( Figure 1a ). In addition, isolated mitochondria from CEM/Bcl-2 cells were shown to have higher O 2 À as compared to those of CEM/Neo cells, assessed by a lucigenin-based chemiluminescence assay and a flow cytometry-based assay using MitoSOX Red (Figure 1b and c) .
Cancer cells overexpressing Bcl-2 have increased coupled mitochondrial respiration and COX activity. Measurement of COX activity revealed that both HeLa/Bcl-2 and CEM/Bcl-2 cells had higher activity than their non-overexpressing counterparts. In addition, N,N,N',N'-tetramethylbenzene-1,4-diamine (TMPD)/ascorbate-driven mitochondrial respiration displayed higher oxygen consumption in CEM/Bcl-2 cells than CEM/Neo cells, translatable to a higher level of COX activity in CEM/Bcl-2 cells (Figure 2a ). This is in concordance with the data from COX activity assays. Increased COX activity will expectedly enhance mitochondrial respiration, with increased ROS production being a derivative. Similarly, succinate-driven mitochondrial oxygen consumption was also higher in CEM/Bcl-2 cells than CEM/Neo cells (Figure 2b ). With COX activity assay and oxygen consumption measurement, we showed that both the oxidative and reductive capacities of COX were enhanced in the context of increased Bcl-2 expression. Bcl-2 expression exerts an effect on COX activity and impacts subsequent O 2 À production. HeLa/Neo cells were transiently transfected with bcl-2 to provide us with another tumor model to test our hypothesis. Overexpression of Bcl-2 observed 24 h after transfection correlated with the increase in COX activity in these cells (Figure 3a and b) . Correspondingly, intracellular O 2 À level in these post-24 h transfectants also increased (Figure 3c ). In contrast, using Bcl-2-specific siRNA, the expression of Bcl-2 was markedly reduced in HeLa/Bcl-2 cells 48 h after transfection (Figure 3d ). Silencing of Bcl-2 effected a decrease in COX activity, which correlated with a drop in intracellular O 2 À level in these Bcl-2-silenced cells (Figure 3e and f) . Silencing of Bcl-2 resulted in the reversal of observations obtained from our transient overexpression studies, further corroborating the likelihood of a functional association between COX and Bcl-2. Moreover, treatment of CEM/Bcl-2 cells with 4 mM HA14-1 (BH3 inhibitor) for 2 h resulted in decreased oxygen consumption of isolated mitochondria (Figure 3g ). In contrast, CEM/Neo cells treated likewise with HA14-1 elicited an increase in oxygen consumption ( Figure 3g ). This observation was analogous to an earlier report on the effect of HA14-1 on mitochondrial respiration in CEM cells. If Bcl-2 overexpression is indeed responsible for higher COX activity and oxygen consumption, which in turn induces a pro-oxidant state, then inhibition of COX should theoretically bring down O 2 À production. The dose-dependent inhibition profile of COX activity by sodium azide revealed that 100mM sodium azide was sufficient to reduce COX activity and oxygen consumption in CEM/Bcl-2 cells to a level similar to that of untreated CEM/Neo cells (Figure 3h ). Using the same concentration of sodium azide, intramitochondrial O 2 À in CEM/ Bcl-2 cells was reduced to a level similar to that of untreated CEM/Neo cells ( Figure 3i ).
Homeostatic regulation of mitochondrial respiration and COX activity in tumor cells overexpressing Bcl-2 during oxidative stress. Antimycin A has been shown to induce intramitochondrial ROS production by inhibiting Complex III. 2 We treated isolated mitochondria with 5 mg/ml antimycin A, which was sufficient to inhibit succinate-driven oxygen consumption and increase O 2 À production from the isolated mitochondria of both CEM/Neo and CEM/Bcl-2 cells almost immediately (Supplementary Figure S2) . Using this property of antimycin A, both CEM/Neo and CEM/Bcl-2 cells were treated for 1 h with the concentration of antimycin A (5 mg/ml) required to induce oxidative stress. Oxygen consumption was initiated and measured in isolated mitochondria, respiring on 1 mM TMPD and 5 mM ascorbate. Comparing TMPD/ascorbate-driven mitochondrial respiration, oxygen consumption in antimycin A-treated CEM/Bcl-2 cells was similar to that of treated CEM/Neo cells ( Figure 4a . COX activity assay and O 2 À determination by lucigenin was performed on siRNA-transfected HeLa/Bcl-2 cells to observe the impact of Bcl-2 silencing. (g) Oxygen consumption was reduced in CEM/Bcl-2 cells treated with HA14-1. CEM/Bcl-2 cells were initially treated with HA14-1 for 2 h before isolated mitochondria were subjected to oxygen consumption measurements. Isolated mitochondria respired on succinate, a Complex II substrate and State 3 respiration was used as basis for comparison. As a control, isolated mitochondria of CEM/Neo cells treated likewise with HA14-1 resulted in increased oxygen consumption, similar to observations reported elsewhere. 17 activity (Figure 4f ). Hence, it was beguiling to notice that the COX activity was on an upward trend in both rotenone-treated HeLa/Neo and HeLa/Bcl-2 cells, albeit HeLa/Neo cells increased nearly twice as much as HeLa/Bcl-2 cells (Figure 4g ). We postulate that this disparity in modulation upon rotenone-and antimycin A-induced oxidative burst could be due to the difference in topology where ROS is accumulated, in relation to the localization of Bcl-2.
It is important to note that the variations in COX activity and oxygen consumption upon antimycin A or rotenone treatments is neither due to a compromise in viability of CEM/Bcl-2 cells nor a proliferative effect on CEM/Neo cells (Supplementary Figure S3A , B). (Figure 5b ). These data argue in favor of a direct effect of Bcl-2 on COX and mitochondrial respiration within the mitochondria. We speculate that the ability of Bcl-2 overexpressing tumor cells to fine-tune mitochondrial respiration by downregulating its COX activity in times of oxidative stress must have a role in controlling ROS levels within the mitochondria. (Figure 6b ). These data suggest that the changes in COX activity and mitochondrial respiration were most likely due to a gain or loss of function in COX activity, rather than an effect on its expression.
Besides, antimycin A-induced downregulation of COX activity in CEM/Bcl-2 cells is a function of intramitochondrial O 2 À and not an effect of the inhibitor itself. TMPD/ascorbateinduced oxygen consumption remained higher in CEM/Bcl-2-isolated mitochondria than CEM/Neo both before and after direct antimycin A treatment (Figure 6c ). This is presumably because no oxidative burst was produced by antimycin A as TMPD/ascorbate-dependent respiration was downstream of Complex III inhibition and any upstream substrate (e.g. succinate) was absent. Likewise, preincubation of isolated COX with increasing doses of antimycin A for 1 h without succinate did not elicit any change in COX activity in both HeLa/Neo and HeLa/Bcl-2 cells, further confirming the role of stress-induced O 2 À in Bcl-2-regulated COX activity (Figure 6c ). Co-treatment of CEM/Bcl-2 cells with 5 mg/ml antimycin A and 20 mM N-acetyl cysteine (NAC) for 1 h did not result in downregulation of COX activity, unlike initial treatment with antimycin A for 1 h followed by NAC for another 1 h (Figure 6d) . Taken together, these data indicate that in the presence of electron transport blockade by complex inhibition results in an upregulation of downstream COX activity regardless of O 2 À status, unless in the context of Bcl-2 overexpression. Furthermore, antimycin A-induced downregulation of COX activity in CEM/Bcl-2 cells was irreversible even upon scavenging intracellular ROS.
Discussion
Our study revealed that tumor cells stably overexpressing Bcl-2 have marked increase in oxygen consumption and COX activity, which primarily accounts for the higher mitochondrial O 2 À produced and in turn, contributing at least in part, to the slight pro-oxidant state in CEM/Bcl-2 cells. 9 More importantly, the impact of Bcl-2 on mitochondrial respiration is not unidirectional. Periods of oxidative distress lead to adjustment in oxygen consumption and COX activity, facilitated by the overexpression of Bcl-2. We propose the modulation in mitochondrial respiration as a novel mechanism to regulate ROS level at an optimal threshold, favoring survival even in the presence of ROS inducers such as antimycin A or serum deprivation. This protective mechanism, together with other classical antioxidant defence systems such as superoxide dismutase (SOD), prevents ROS production from reaching detrimental levels. In our system, we reason that the involvement of SOD in mediating the maintenance of mitochondrial O 2 À in CEM/Bcl-2 cells during antimycin A treatment is at best, minimal. The SOD isoform responsible for quenching mitochondrial O 2 À is predominantly MnSOD (SOD II), which has been shown to localize to the mitochondrial matrix. On the other hand, the production of O 2 À by antimycin A inhibition of Complex III was reported to be largely confined to the cytoplasmic side of the inner mitochondrial membrane. 21 In other words, most of the ROS produced is extruded and strewn within the intermembrane space. Moreover, previous work has also shown that O 2 À in its anionic form is too strongly charged to readily cross the inner mitochondrial membrane. 22 On the basis of this knowledge, it seems unlikely for MnSOD to be able to access the It has been reported that HA14-1 increased mitochondrial respiration due to uncoupling and led to ROS production in CEM cells. 17 Indeed, we reported increased oxygen consumption in CEM/Neo cells treated in similar fashion. However, we reason two possible alternative scenarios for our observation in CEM/Bcl-2 cells. Firstly, it may be likely that the reduction in oxygen consumption caused by the inhibition of Bcl-2 could more than compensate for the intrinsic capability of HA14-1 to raise uncoupled mitochondrial respiration in CEM/Bcl-2 cells, with the outcome being reduced ROS generation and overall decreased oxygen consumption. On the other hand, the result of increased uncoupled mitochondrial respiration and ROS production in CEM cells as reported previously was observed in the absence of Bcl-2 overexpression. Thus, it may be conceivable that the overexpression of Bcl-2 abrogates the effect of HA14-1 by sensing ROS status and downregulating mitochondrial respiration accordingly to maintain ROS at a manageable level. Indeed, if Bcl-2 inhibitor HA14-1 uncouples mitochondrial respiration in CEM cells, it might be plausible to imply that Bcl-2 would make an unlikely uncoupling candidate. 17 Nevertheless, from the respiratory control exerted by Bcl-2 on the rate-limiting enzyme COX, its appears that the CEM/ Bcl-2 cells are able to discern between the threat posed by potentially overwhelming ROS and the 'energy cutoff' triggered by antimycin A, adjusting mitochondrial respiration accordingly to keep ROS level under control. The regulation of COX activity and oxygen consumption brought respirationdependent O 2 À production under control and this may be effective in protecting cells against mitochondrial dysfunction and ROS-induced apoptosis.
It is promising to unravel the workings of antiapoptotic proteins, in the like of Bcl-2 on metabolism and respiration. The establishing of this relationship between Bcl-2 and COX opens up a new paradigm in apoptotic evasion by cancer cells and their altered sensitivities to treatment with ROS-inducing chemotherapeutics. By virtue of an increased Bcl-2 expression profile, cancer cells might be able to remain resistant to ROS-inducing death triggers by elegantly manipulating their mitochondrial respiration profiles, keeping potentially deleterious level of ROS at bay, whereas maintaining a slight prooxidant milieu under basal conditions, conducive for survival. Our work suggests that the engagement of the mitochondrial respiration machinery contributes to this phenomenon.
Materials and Methods
Cell culture. CEM human leukemia cells stably transfected with the control vector (CEM/Neo) or Bcl-2 (CEM/Bcl-2) were maintained in RPMI 1640 supplemented with 2 mM L-glutamine, 1% streptomycin-penicillin (v/v) and 5% fetal bovine serum (FBS; v/v). G418 disulphate salt solution was added as a selective antibiotic for the maintenance of stable transfectants. Jurkat cells were from human T-cell leukemia stably transfected with the above-mentioned vectors and cultured under conditions as described previously. HeLa cells were derived from cervical carcinoma, which have been transformed by human papillomavirus 18 (HPV18). These cells were stably transfected with the same vectors as described for CEM and Jurkat cells and maintained in Dulbecco's modified Eagle's medium containing 10% FBS (v/v). All the cell lines were cultured in a humidified incubator at 371C and 5% CO 2 .
Isolation of intact mitochondria. Cells were harvested and washed once with ice-cold 1 Â PBS and spun down by centrifugation at 1200 r.p.m. for 5 min at 41C. The pellet was resuspended in 10 volumes of extraction buffer (200 mM mannitol, 68 mM sucrose, 50 mM Pipes-KOH (pH 7.4), 50 mM KCl, 5 mM EGTA, 2 mM MgCl 2 and1 mM dithiothreitol), containing various protease inhibitors (1 mM phenylmethanesulfonylfluoride, 10 mg/ml aprotinin, 20 mg/ml pepstatin A and 10 mg/ml leupeptin) and incubated on ice for 20 min. After incubation, the cells were homogenized with a dounce homogenizer and passaged for 30 strokes before being centrifuged at 300 Â g for 10 min at 41C. Following which, the supernatant was centrifuged again at 12000 Â g for 30 min at 41C. The pellet contains the intact mitochondria fraction.
Oxygen consumption. Oxygen consumption was measured using Oxytherm Electrode (Hansatech Instruments, Norfolk, UK) at 251C. The chambers were cleaned with distilled water. Isolated mitochondria were added to each chamber containing 1.25 ml of mitochondrial buffer III (200 mM mannitol, 75 mM sucrose, 10 mM Tris-HCL (pH 7.4), 0.1 mM EDTA, 10 mM K 2 HPO 4 and 10 mM KCl). State 4 mitochondrial respiration was stimulated by adding 10 mM succinate, 80 mM ATP and 5 mM rotenone. State 3 respiration was initiated with 0.2 mM ADP. Data acquisition and analysis was carried out using Oxygraph Plus developed for high-resolution respirometry (Hansatech Instruments, Norfolk, UK).
Cytochrome c oxidase isolation and activity. Cells were dissolved in 2 ml of COX buffer (250 mM sucrose, 2 mM HEPES and 0.1 mM EGTA at pH 7.4) before being centrifuged at 330 Â g for 10 min at 41C. The cells were then resuspended with 1 ml of COX buffer and incubated for 10 min at 41C before being subjected to homogenization for 10 passages and the cell lysate was spun at 600 Â g for 10 min at 41C. The supernatant was then centrifuged at 14 400 Â g for 10 min at 41C. The resultant pellet is the purified mitochondria fraction, containing COX. The pellet was dissolved in 100 ml of prewarmed potassium phosphate buffer at pH 7.2 and incubated at room temperature (RT) for 3 min. COX activity was measured by monitoring the oxidation of reduced cytochrome c by spectrophotometric analysis at 550 nm for 2 min at 371C using BioSpec-1601 spectrophotometer (Shimadzu, Japan). COX activity was determined by measuring the decrease in absorbance of ferrocytochrome c caused by its oxidation to ferricytochrome c by COX.
Transient transfection. Transient transfection of HeLa/Neo cells was performed using the SuperFect s Transfection Reagents from QIAGEN GmbH (Germany). Briefly, 3 mg of the pIRES (empty vector) or pcDNA3-Bcl-2 was added to 20 ml of the SuperFect s Transfection Reagent and transfection was carried out as recommended by the vendor. Bcl-2 expression was detected from the cell lysates at the various post-transfection time points by Western blotting using a primary mouse monoclonal anti-Bcl-2 antibody at 1:1000 dilution (Santa Cruz, CA, USA) and a secondary horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG at 1:5000 dilution (Pierce, IL, USA).
RNA interference. HeLa/Bcl-2 cells were transfected 96, 72 and 48 h before COX activity and O 2 À measurement experiments with 0.2 mM Bcl-2-specific siRNA (QIAGEN, GmbH, Germany) or scrambled siRNA duplexes by using Oligofectaminet reagent according to the manufacturer's instructions (Invitrogen, CA, USA). Expression level of Bcl-2 was confirmed by Western blotting using antibodies as described previously for the detection of Bcl-2.
O 2
À measurement by lucigenin. A lucigenin-based chemiluminescence assay was used for measuring intracellular O 2 À as described previously. 23 Chemiluminescence was monitored using a Berthold Sirius Luminometer (Berthold detection systems GmbH, Bleichstrabe/Pforzheim/Germany). The assay was also used to detect O 2 À level in isolated mitochondria in some instances. Data are described as relative light units/s/mg of protein (RLU/s/mg protein).
À measurement by MitoSOX Red. O 2 À production from the mitochondria was also specifically monitored by MitoSOX Red (Invitrogen, CA, USA), which is a fluorescent probe targeted to the mitochondria and highly susceptible to oxidation by O 2 À . Briefly, 1 Â 10 6 cells were incubated with 10 mM MitoSOX Red reagent for 15 min at 371C. Cells were washed twice with 1 Â PBS and immediately analyzed in Epic Profile flow cytometer with excitation set at 510 nm. Data were analyzed for 10 000 events using the WinMDI software.
Western blotting. Proteins were analyzed and resolved on a 12% (v/v) acrylamide resolving gel, subjected to SDS-PAGE. The resolved proteins were then transferred onto a polyvinyldifluoride (PVDF) membrane by the semi-dry transfer method using the Hoefert TE 77 semi-dry transfer unit (Amersham Biosciences, NJ, USA). The membrane was then blocked with 5% (w/v) fat-free milk in Trisbuffered saline containing 0.05% (v/v) Tween 20 (TBST) for 1 h. After three washes with TBST to remove excess milk, the membrane was probed for the protein of interest with the relevant primary antibody in 5% (w/v) bovine serum albumin in TBST at 41C for 1-2 h. The membrane was subsequently subjected to three washes with TBST to remove unbound primary antibody and probed again with the appropriate HRP-conjugated secondary antibody in TBST containing 1% (w/v) fatfree milk for 1 h at RT. After three washes with TBST to remove any excess unbound secondary antibody, the desired probed proteins were next detected with Kodak Biomax MR X-ray film by enhanced chemiluminescence using the SuperSignal Chemiluminescent Substrate (Pierce, IL, USA). The primary and secondary antibodies for the probing by Western blot analysis were applied at 1 : 1000 and 1 : 5000 dilutions, respectively.
Cell viability assay. Cells were added with 3 mg/ml of 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl tetrazolium bromide in plain RPMI 1640 and incubated for 1-2 h at 371C. The cells were then centrifuged at 3000 Â r.p.m. for 5 min before being redissolved in DMSO, containing Sorensen's glycine buffer (0.1 M glycine and 0.1 M NaCl, pH 10.5). Cell viability was determined spectrophotometrically, with absorbance wavelength of 570 nm.
